INVA
Price
$19.21
Change
-$0.19 (-0.98%)
Updated
Jul 3 closing price
Capitalization
1.21B
23 days until earnings call
SCPH
Price
$3.88
Change
-$0.09 (-2.27%)
Updated
Jul 7, 01:20 PM (EDT)
Capitalization
209.58M
30 days until earnings call
Interact to see
Advertisement

INVA vs SCPH

Header iconINVA vs SCPH Comparison
Open Charts INVA vs SCPHBanner chart's image
Innoviva
Price$19.21
Change-$0.19 (-0.98%)
Volume$617.66K
Capitalization1.21B
scPharmaceuticals
Price$3.88
Change-$0.09 (-2.27%)
Volume$328
Capitalization209.58M
INVA vs SCPH Comparison Chart in %
Loading...
INVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INVA vs. SCPH commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INVA is a Buy and SCPH is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (INVA: $19.21 vs. SCPH: $3.97)
Brand notoriety: INVA and SCPH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INVA: 72% vs. SCPH: 54%
Market capitalization -- INVA: $1.21B vs. SCPH: $209.58M
INVA [@Biotechnology] is valued at $1.21B. SCPH’s [@Biotechnology] market capitalization is $209.58M. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INVA’s FA Score shows that 1 FA rating(s) are green whileSCPH’s FA Score has 0 green FA rating(s).

  • INVA’s FA Score: 1 green, 4 red.
  • SCPH’s FA Score: 0 green, 5 red.
According to our system of comparison, INVA is a better buy in the long-term than SCPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INVA’s TA Score shows that 6 TA indicator(s) are bullish while SCPH’s TA Score has 4 bullish TA indicator(s).

  • INVA’s TA Score: 6 bullish, 4 bearish.
  • SCPH’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, INVA is a better buy in the short-term than SCPH.

Price Growth

INVA (@Biotechnology) experienced а -5.79% price change this week, while SCPH (@Biotechnology) price change was -0.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.35%. For the same industry, the average monthly price growth was +13.82%, and the average quarterly price growth was -0.82%.

Reported Earning Dates

INVA is expected to report earnings on Jul 30, 2025.

SCPH is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+5.35% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INVA($1.21B) has a higher market cap than SCPH($210M). SCPH YTD gains are higher at: 12.147 vs. INVA (10.720). INVA has higher annual earnings (EBITDA): 681K vs. SCPH (-83.9M). INVA has more cash in the bank: 447M vs. SCPH (57.5M). SCPH has less debt than INVA: SCPH (52.4M) vs INVA (451M). INVA has higher revenues than SCPH: INVA (370M) vs SCPH (42M).
INVASCPHINVA / SCPH
Capitalization1.21B210M574%
EBITDA681K-83.9M-1%
Gain YTD10.72012.14788%
P/E Ratio51.97N/A-
Revenue370M42M881%
Total Cash447M57.5M777%
Total Debt451M52.4M861%
FUNDAMENTALS RATINGS
INVA vs SCPH: Fundamental Ratings
INVA
SCPH
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
65
Fair valued
PROFIT vs RISK RATING
1..100
59100
SMR RATING
1..100
93100
PRICE GROWTH RATING
1..100
5542
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SCPH's Valuation (65) in the Pharmaceuticals Major industry is in the same range as INVA (74) in the Pharmaceuticals Other industry. This means that SCPH’s stock grew similarly to INVA’s over the last 12 months.

INVA's Profit vs Risk Rating (59) in the Pharmaceuticals Other industry is somewhat better than the same rating for SCPH (100) in the Pharmaceuticals Major industry. This means that INVA’s stock grew somewhat faster than SCPH’s over the last 12 months.

INVA's SMR Rating (93) in the Pharmaceuticals Other industry is in the same range as SCPH (100) in the Pharmaceuticals Major industry. This means that INVA’s stock grew similarly to SCPH’s over the last 12 months.

SCPH's Price Growth Rating (42) in the Pharmaceuticals Major industry is in the same range as INVA (55) in the Pharmaceuticals Other industry. This means that SCPH’s stock grew similarly to INVA’s over the last 12 months.

INVA's P/E Growth Rating (2) in the Pharmaceuticals Other industry is significantly better than the same rating for SCPH (100) in the Pharmaceuticals Major industry. This means that INVA’s stock grew significantly faster than SCPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INVASCPH
RSI
ODDS (%)
Bullish Trend 5 days ago
69%
Bearish Trend 5 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
65%
Bullish Trend 5 days ago
74%
Momentum
ODDS (%)
Bearish Trend 5 days ago
62%
Bullish Trend 5 days ago
70%
MACD
ODDS (%)
Bearish Trend 5 days ago
46%
Bearish Trend 5 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
60%
Bearish Trend 5 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
61%
Bullish Trend 5 days ago
81%
Advances
ODDS (%)
Bullish Trend 22 days ago
67%
Bullish Trend 6 days ago
77%
Declines
ODDS (%)
Bearish Trend 5 days ago
63%
Bearish Trend 8 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
86%
Bearish Trend 5 days ago
90%
Aroon
ODDS (%)
Bullish Trend 5 days ago
69%
Bullish Trend 5 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
INVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BMGKX45.580.48
+1.06%
BlackRock Mid-Cap Growth Equity K
PSECX18.720.10
+0.54%
1789 Growth and Income C
VBPIX21.960.09
+0.41%
Vanguard Baillie GiffordGlbPstvImpStkInv
JNRRX56.170.04
+0.07%
PGIM Jennison Natural Resources R
DIFHX12.38N/A
N/A
MFS Diversified Income R6

INVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, INVA has been loosely correlated with GBIO. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if INVA jumps, then GBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INVA
1D Price
Change %
INVA100%
-0.98%
GBIO - INVA
38%
Loosely correlated
+1.51%
INBX - INVA
37%
Loosely correlated
+3.75%
KALV - INVA
36%
Loosely correlated
+1.70%
CPRX - INVA
36%
Loosely correlated
+0.05%
SCPH - INVA
36%
Loosely correlated
-1.73%
More

SCPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCPH has been loosely correlated with CRSP. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if SCPH jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCPH
1D Price
Change %
SCPH100%
-1.73%
CRSP - SCPH
45%
Loosely correlated
+0.97%
AURA - SCPH
45%
Loosely correlated
+1.55%
BEAM - SCPH
45%
Loosely correlated
+0.65%
AUTL - SCPH
44%
Loosely correlated
+0.85%
YMAB - SCPH
43%
Loosely correlated
+0.94%
More